We are delighted to announce the successful conclusion of a significant transaction between Hycon and Pfizer’s Singapore division. This strategic sale involves the full transfer of Hycon’s advanced pharmaceutical manufacturing technology and associated assets to Pfizer, strengthening their regional production capabilities. The deal includes the handover of proprietary equipment and process documentation.

Throughout the negotiation and transition phases, our engineering and legal teams collaborated closely with Pfizer’s Singapore facility to ensure a smooth handover, achieving operational readiness within just 12 weeks. The transfer also includes comprehensive support and training services, ensuring seamless continuity of production and quality standards.

This partnership underscores Pfizer’s commitment to expanding its footprint in Asia and enhances Hycon’s legacy through integration into a world-class global pharmaceutical organization. We extend our sincere thanks to all teams involved for their dedication and professionalism in delivering this important milestone.